Author(s):
Nigar K. Mujawar, Jameel Ahmed S. Mulla
Email(s):
jameelahmed5@rediffmail.com
DOI:
10.52711/0974-360X.2025.00886 
Address:
Nigar K. Mujawar1,2, Jameel Ahmed S. Mulla3*
1Research Scholar, Shree Santkrupa College of Pharmacy, Ghogaon, Karad 415111, Maharashtra, India.
2Associate Professor, Department of Pharmaceutics, Womens College of Pharmacy, Peth Vadgaon Kolhapur 416112, Maharashtra, India.
3Professor, Department of Pharmaceutics, Shree Santkrupa College of Pharmacy, Ghogaon, 415111 Karad, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
The utilization of lipid polymer hybrid nanoparticles as a means of cancer treatment, especially for breast cancer, provides great hope for cancer management. This abstract is an overview of lipid polymer hybrid nanoparticles and why they are very important in targeted drug delivery in the fight against breast cancer. It begins with examining the structure and formulation of lipid polymer hybrid nanoparticles, which are hybrids given the presence of lipid and polymer components in them. A discussion of synthesis procedures and properties of lipid polymer hybrid nanoparticles is presented; it takes into account both the disadvantages intrinsic to them, such as synthesis complexity, and the advantages, such as improved drug stability and controlled release kinetics. The abstract further explores the operation of targeted drug delivery systems, with major emphasis being placed on how drug delivery techniques based on nanoparticles are important.in enhancing therapeutic outcomes. The obtained capabilities of lipid polymer hybrid nanoparticles to provide therapeutic agents to tumor sites with minimal off-target effects are focused on the breast cancer therapy area. Mechanisms by which lipid polymer hybrid nanoparticles function to enable targeted drug delivery and regulated release in the tumor microenvironment are revealed through their methods of action. With all their fabulous promise, however, they are still bound by normal biological limitations and regulatory obstacles. Designing strategies for personalized treatment and modifying the design of nanoparticles in the future will be crucial to overcoming these challenges. Finally, further study may be used to achieve the potential for lipid polymer hybrid nanoparticles in clinical applications and offer a potential methodology for the improvement of breast cancer therapy effectiveness and safety.
Cite this article:
Nigar K. Mujawar, Jameel Ahmed S. Mulla. Targeted Drug Delivery: Revolutionizing Breast Cancer Treatment with Lipid Polymer Hybrid Nanoparticles. Research Journal Pharmacy and Technology. 2025;18(12):6131-8. doi: 10.52711/0974-360X.2025.00886
Cite(Electronic):
Nigar K. Mujawar, Jameel Ahmed S. Mulla. Targeted Drug Delivery: Revolutionizing Breast Cancer Treatment with Lipid Polymer Hybrid Nanoparticles. Research Journal Pharmacy and Technology. 2025;18(12):6131-8. doi: 10.52711/0974-360X.2025.00886 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-76
REFERENCES:
1. Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. International Journal of Nanomedicine. 2019; Mar 19: 1937-52. doi:10.2147/IJN.S198353
2. Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (plns) as emerging drug delivery platform—A comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021; Aug 18; 13(8): 1291. doi:10.3390/pharmaceutics13081291
3. Miri V, Jangde RK, Singh D, Suresh PK. Lipid-Polymer Hybrid Nanoparticles for Topical Drug Delivery System. Journal of Drug Delivery and Therapeutics. 2023; Apr 15; 13(4): 113-20. doi:10.22270/jddt. v13i4.5789
4. Parveen S, Gupta P, Kumar S, Banerjee M. Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics. Medicine in Drug Discovery. 2023; Oct 30: 100165. doi: 10.1016/j.medidd.2023.100165
5. Shaw I, Boafo GF, Ali YS, Liu Y, Mlambo R, Tan S, Chen C. Advancements and prospects of lipid-based nanoparticles: dual frontiers in cancer treatment and vaccine development. Journal of Microencapsulation. 2024; Apr 2; 41(3): 226-54. doi:10.1080/02652048.2024.2326091
6. Raikwar S, Jain SK. Nano-Based Drug Delivery System: An Overview and Future Prospective. Smart Nanocarrier for Effective Drug Delivery.:126-43, 2024.
7. Jain S, Kumar M, Kumar P, Verma J, Rosenholm JM, Bansal KK, Vaidya A. Lipid–polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery. Journal of Functional Biomaterials. 2023; Aug 23; 14(9): 437.doi:10.3390/jfb14090437
8. Peng Y, Bariwal J, Kumar V, Tan C, Mahato RI. Organic nanocarriers for delivery and targeting of therapeutic agents for cancer treatment. Advanced Therapeutics. 2020; Feb; 3(2): 1900136. doi:10.1002/adtp.201900136
9. Fadholly A, Ansori AN, Sucipto TH. An overview of naringin: Potential anticancer compound of citrus fruits. Research Journal of Pharmacy and Technology. 2020; Nov 13; 13(11): 5613-9. doi:10.5958/0974-360X.2020.00979.8
10. Shetty R, Mathew RT, Vijayakumar M. Incidence and pattern of distribution of cancer in India: A secondary data analysis from six population-based cancer registries. Cancer Research, Statistics, and Treatment. 2020; Oct 1; 3(4): 678-82. doi: 10.4103/crst.crst_290_20
11. Hariramani N, Jayanthi S. A systematic review of intrinsic factors and its influence in breast cancer. Research Journal of Pharmacy and Technology. 2018; 11(8): 3543-6. doi:10.5958/0974-360X.2018.00654.6.
12. Patidar A, Shivhare SC, Ateneriya U, Choudhary S. A Comprehensive Review on Breast Cancer. Asian Journal of Nursing Education and Research. 2012; 2(1): 28.
13. Geetha M, Menaka K, Padmavathi P. Awareness of Breast self-examination and risk factors of Breast Cancer among Women. Asian Journal of Nursing Education and Research. 2017; 7(3): 413-6. doi: 10.5958/2349-2996.2017.00082.9
14. Dange VN, Shid SJ, Magdum CS, Mohite SK. A review on breast cancer: an overview. Asian Journal of Pharmaceutical Research. 2017; 7(1): 49-51. doi: 10.5958/2231-5691.2017.00008.9
15. Tiwari A, Singh M, Sahu B. Risk factors for breast cancer. International Journal of Nursing Education and Research. 2022; 10(3): 276-82. 10.52711/2454-2660.2022.00065
16. Srivastava S, Kumar A. Breast cancer survivorship among Indian women: an overview. Asian Journal of Nursing Education and Research. 2022; 12(3): 262-6. 10.52711/2349-2996.2022.00056
17. Sudhakar GK, Pai V, Pai A. An overview on current strategies in breast cancer therapy. Research Journal of Pharmacology and Pharmacodynamics. 2013; 5(6): 353-5.
18. Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Molecular Cancer. 2023; Oct 3; 22(1): 160. doi:10.1186/s12943-023-01849-0
19. Persano F, Gigli G, Leporatti S. Lipid-polymer hybrid nanoparticles in cancer therapy: Current overview and future directions. Nano Express. 2021; Mar 18; 2(1): 012006. doi:10.1088/2632-959X/abeb4b
20. Rajana N, Mounika A, Chary PS, Bhavana V, Urati A, Khatri D, Singh SB, Mehra NK. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. Journal of Controlled Release. 2022; Dec 1; 352: 1024-47. doi: 10.1016/j.jconrel.2022.11.009
21. Srivastava S, Kumar A. Breast cancer survivorship among Indian women: an overview. Asian Journal of Nursing Education and Research. 2022; 12(3): 262-6. doi:10.52711/2349-2996.2022.00056
22. Purwiningsih S, Arni F, Parmi P, Susianawati DE, Kantohe I, Taurisa A. Knowledge and attitudes of young women regarding BSE at state Junior High School 21 Palu, South Palu District, Palu City, Central Sulawesi. Science Midwifery. 2024; Apr 30; 12(1): 444-51. doi:10.35335/midwifery. v12i1.1494.
23. Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. Journal of the National Cancer Institute. 2005; Oct 5; 97(19): 1428-37.doi:10.1093/jnci/dji290
24. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024; May; 74(3): 229-63. doi:10.3322/caac.21834
25. Ahsan MD, Webster EM, Wolfe IA, McGonigle R, Brewer JT, Chandler IR, Weiss JM, Enriquez A, Cantillo E, Holcomb K, Chapman-Davis E. Personalized survivorship care: Routine breast cancer risk assessment in the Gynecologic Oncology clinic. Gynecologic Oncology. 2024; Apr 1; 183: 47-52. doi: 10.1016/j.ygyno.2024.03.004
26. Oppong R, Yeboah D, Owusu-Ansah M, Salifu SP. Radiotherapy for Breast Cancer in Africa. Advances in Radiation Oncology. 2024; Mar 12: 101488. doi: 10.1016/j.adro.2024.101488
27. Peacock HM, van Walle L, Silversmit G, Neven P, Han SN, Van Damme N. Breast cancer incidence, stage distribution, and treatment shifts during the 2020 COVID-19 pandemic: a nationwide population-level study. Archives of Public Health. 2024; Dec; 82(1): 1-3. doi:10.1186/s13690-024-01296-3
28. Kulothungan V, Ramamoorthy T, Sathishkumar K, Mohan R, Tomy N, Miller GJ, Mathur P. Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme. Breast Cancer Research and Treatment. 2024; Mar 4: 1-0. doi:/10.1007/s10549-024-07264-3
29. Kumar AS, Joshna N, Saha GC, Saha H, Billah MM. A Review of Recent Advancements in Nanotechnology for Medical Drugs Delivery. Research Journal of Pharmacy and Technology. 2024; Apr 22; 17(4): 1891-4. doi:10.52711/0974-360X.2024.00300.
30. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted drug delivery—from magic bullet to nanomedicine: principles, challenges, and future perspectives. Journal of Multidisciplinary Healthcare. 2021; Jul 5: 1711-24. doi:10.2147/JMDH.S313968
31. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nature Reviews Materials. 2021; Apr; 6(4): 351-70. doi:10.1038/s41578-020-00269-6
32. Sharma S, Singh A. Nanotechnology-based targeted drug delivery: current status and future prospects for drug development. Drug Discovery and Development–Present and Future. 2011; Dec 16: 427-63.
33. Singh A, Ansari VA, Ahsan F, Akhtar J, Khushwaha P, Maheshwari S. Viridescent concoction of genstein tendentious silver nanoparticles for breast cancer. Research Journal of Pharmacy and Technology. 2021; 14(5): 2867-72. doi:10.52711/0974-360X.2021.00504.
34. Ahmad W, Khan T, Basit I, Imran J. A Comprehensive Review on Targeted Drug Delivery System. Asian Journal of Pharmaceutical Research. 2022; 12(4): 335-40. doi:10.52711/2231-5691.2022.00053
35. Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. Journal of Drug Targeting. 2007; Jan 1;15(3):163-83.doi:10.1080/10611860701231810
36. Al Bostami RD, Abuwatfa WH, Husseini GA. Recent advances in nanoparticle-based Co-delivery systems for cancer therapy. Nanomaterials. 2022; Aug 4; 12(15): 2672. doi:10.3390/nano12152672
37. Sangtani A, Nag OK, Field LD, Breger JC, Delehanty JB. Multifunctional nanoparticle composites: progress in the use of soft and hard nanoparticles for drug delivery and imaging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2017 Nov;9(6): e1466.doi:10.1002/wnan.1466
38. Sahoo PK. Micro-and nanoscale oral drugs delivery system. Frontiers in Chemical, Biological, and Pharmaceutical Sciences Volume III ISBN: 978-93-95847-85-8.:7.2024
39. Jose C, Amra K, Bhavsar C, Momin MM, Omri A. Polymeric lipid hybrid nanoparticles: properties and therapeutic applications. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2018; 35(6). doi:10.1615/CritRevTherDrugCarrierSyst.2018024751
40. Wu XY. Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery. Expert Opinion on Drug Delivery. 2016; May 3; 13(5): 609-12. doi:10.1517/17425247.2016.1165662
41. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R, Farokhzad OC. Self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; Aug 26; 2(8): 1696-702. doi:10.1021/nn800275r
42. Soares DC, Domingues SC, Viana DB, Tebaldi ML. Polymer-hybrid nanoparticles: Current advances in biomedical applications. Biomedicine and Pharmacotherapy. 2020; Nov 1; 131: 110695. doi: 10.1016/j.biopha.2020.110695
43. Tahir N, Madni A, Correia A, Rehman M, Balasubramanian V, Khan MM, Santos HA. Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy. International Journal of Nanomedicine. 2019; Jul 5: 4961-74.doi:10.2147/IJN.S209325
44. Jangde RK, Khute S. Design and development of ciprofloxacin lipid polymer hybrid nanoparticle by response surface methodology. Research Journal of Pharmacy and Technology. 2020; 13(7): 3249-56. doi:10.5958/0974-360X.2020.00576.4
45. Khalili L, Dehghan G, Sheibani N, Khataee A. Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: Recent advances and challenges. International Journal of Biological Macromolecules. 2022; Jul 31; 213: 166-94.doi: 10.1016/j.ijbiomac.2022.05.156
46. Abdou EM, Fayed MA, Helal D, Ahmed KA. Assessment of the hepatoprotective effect of developed lipid-polymer hybrid nanoparticles (LPHNPs) encapsulating naturally extracted β-Sitosterol against CCl4 induced hepatotoxicity in rats. Scientific Reports. 2019; Dec 24; 9(1):19779.doi:10.1038/s41598-019-56320-2
47. Lv LI, Qiu K, Yu X, Chen C, Qin F, Shi Y, Ou J, Zhang T, Zhu H, Wu J, Liu C. Amphiphilic copolymeric micelles for doxorubicin and curcumin co-delivery to reverse multidrug resistance in breast cancer. Journal of Biomedical Nanotechnology. 2016 May 1;12(5):973-85.doi:10.1166/jbn.2016.2231
48. Alhajamee M, Marai K, Al Abbas SM, Homayouni Tabrizi M. Co-encapsulation of curcumin and tamoxifen in lipid-chitosan hybrid nanoparticles for cancer therapy. Materials Technology. 2022 Jul 29;37(9):1183-94.doi:10.1080/10667857.2021.1926811
49. Afzal M, Alharbi KS, Alruwaili NK, Al-Abassi FA, Al-Malki AA, Kazmi I, Kumar V, Kamal MA, Nadeem MS, Aslam M, Anwar F. Nanomedicine in treatment of breast cancer–A challenge to conventional therapy. InSeminars in Cancer Biology 2021 Feb 1 (Vol. 69, pp. 279-292). Academic Press.doi: 10.1016/j.semcancer.2019.12.016
50. Karim ME. Fabrication and evaluation of biodegradable inorganic-organic hybrid nanoparticles as potential tools for targeted delivery of genes and small interfering RNAs into breast cancer cells (Doctoral Dissertation, Monash University).2019.
51. Mohapatra P, Singh P, Singh D, Sahoo S, Sahoo SK. Phytochemical based nanomedicine: a panacea for cancer treatment, present status and future prospective. Open Nano. 2022 Jul 1; 7: 100055.doi: 10.1016/j.onano.2022.100055
52. Harada S, Ehara S, Ishii K, Sato T, Koka M, Kamiya T, Sera K, Goto S. Tumor CT imaging using targeted nanoparticle delivery for contrast enhancement and tumor inhibition using targeted release of carboplatin nanoparticles via radiotherapy. International Journal of PIXE. 2014; Nov 27; 24(03n04): 137-49. doi:10.1142/S0129083514400075
53. de Sousa Victor R, Marcelo da Cunha Santos A, Viana de Sousa B, de Araújo Neves G, Navarro de Lima Santana L, Rodrigues Menezes R. A review on Chitosan’s uses as a biomaterial: Tissue engineering, drug delivery systems, and cancer treatment. Materials. 2020 Nov 6;13(21):4995.doi:10.3390/ma13214995
54. Sartaj A, Qamar Z, Qizilbash FF, Annu, Md S, Alhakamy NA, Baboota S, Ali J. Polymeric nanoparticles: Exploring the current drug development and therapeutic insight of breast cancer treatment and recommendations. Polymers. 2021 Dec 15;13(24):4400.doi:10.3390/polym13244400
55. Qureshi MA, Khan MY, Imran A, Maqsood Q, Hussain N, Ali SW. Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine. 2024.1-27.
56. Mandadi SR, Srinivas L, Prasad VR. Advances in Nanomaterials-Based Carrier System for the Treatment of Breast Cancer 2021.
57. Tung BT, Quynh CT, Hong NK. Nanotechnology applications in breast cancer. InHandbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics 2022 (pp. 442-465). IGI Global.doi:10.4018/978-1-7998-9258-8.ch020
58. Gamper C. Plant virus-derived nanoparticles for the imaging and treatment of cancer (Doctoral dissertation, Université de Strasbourg). 2019.
59. Warrier DU, Desai HR, Singh KH, Shinde UA. Solid Lipid Nanoparticle-Based Drug Delivery for Lung Cancer. InHandbook of Lung Targeted Drug Delivery Systems. 2021; Oct 17 (pp. 303-323). CRC Press.
60. Garg NK, Tandel N, Jadon RS, Tyagi RK, Katare OP. Lipid–polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions. Drug Discovery Today. 2018; Sep 1; 23(9): 1610-21.doi: 10.1016/j.drudis.2018.05.033
61. Narwade M, Shaikh A, Gajbhiye KR, Kesharwani P, Gajbhiye V. Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery. Biomaterials Research. 2023; May 6; 27(1): 42. doi:10.1186/s40824-023-00365-y
62. Mahor AK, Singh PP, Gupta R, Bhardwaj P, Rathore P, Kishore A, Goyal R, Sharma N, Verma J, Rosenholm JM, Bansal KK. Nanostructured lipid carriers for improved delivery of therapeutics via the oral route. Journal of Nanotechnology. 2023; Nov 6; 2023: 1-35. doi:10.1155/2023/4687959
63. Uddin MN, Roni MA. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines. 2021; Sep 17; 9(9): 1033.doi:10.3390/vaccines9091033
64. Ding S, Anton N, Vandamme TF, Serra CA. Microfluidic nanoprecipitation systems for preparing pure drug or polymeric drug-loaded nanoparticles: an overview. Expert Opinion on Drug Delivery. 2016; Oct 2; 13(10): 1447-60.doi:10.1080/17425247.2016.1193151
65. Bose RJ, Ravikumar R, Karuppagounder V, Bennet D, Rangasamy S, Thandavarayan RA. Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges. Drug Discovery Today. 2017; Aug 1; 22(8): 1258-65. doi: 10.1016/j.drudis.2017.05.015